NIH R01 · 2024
Rewired Metabolism and Immunosuppression in MYCN-driven Neuroblastoma
PROJECT SUMMARY Amplification of the oncogene MYCN drives high-risk progressive disease, resistance to therapy, and a poor overall survival rate below 45% for high-risk neuroblastoma (NB) patients. Further, more than half of all high-risk patients will relapse, and the post-relapse survival rate is only 10%. MYCN-driven NB tumors have poor immune responses due to a relatively low mutational load, low MHC-I expression, and reduced immune cell infiltration. As a result, NB is often immunologically quiescent, thus limiting immunotherapy approaches. MYCN amplification has a central role in orchestrating the metabolic reprogramming that favors NB growth and adaptation to its microenvironment.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.